A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Imlunestrant (Inluriyo)

Estrogen Receptor Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2025-09-25
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
325 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Imlunestrant used for?

Imlunestrant is a Estrogen Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Imlunestrant?

No. Imlunestrant is brand-only with no generic equivalents currently in market.

How much does my plan pay for Imlunestrant?

NADAC pricing data not currently available for this drug.

Is Imlunestrant on the FDA shortage list?

No. Imlunestrant is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Estrogen Receptor Antagonist2 alternatives in D1
01
Elacestrant
Brand: ORSERDU
Lowest NADAC
0Generic mfrs
$428.9MCY24 Part D spend
Compare →
02
Fulvestrant
Brand: FASLODEX
Lowest NADAC
13Generic mfrs
$8.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.